Experience of ivabradine application in patients with comorbid pathology
- Authors: Kochetkova I.V1, Chernykh T.M1
-
Affiliations:
- N.N.Burdenko Voronezh State Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 18, No 1 (2016)
- Pages: 80-82
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94413
- ID: 94413
Cite item
Full Text
Abstract
The aim of the study is to assess the antiarrhythmic action of ivabradine in patients with comorbid pathology, and associated with the combination of effort angina and chronic obstructive pulmonary disease following coronary artery bypass graft surgery.Materials and methods: we examined 120 men with stable effort angina functional classes II-III 3 years after coronary artery bypass graft surgery using the hardware-software complexes “ETON” and “Holter-DMS”. The article describes the following results: the application of ivabradine can reduce ventricular extrasystoles.Conclusion: we recommend using ivabradine in patients with ischemic heart disease combined with chronic obstructive pulmonary disease after coronary artery bypass graft surgery because of significant antianginal effect of this drug: such as reducing the number of angina attacks, improving the quality of life of patients, increasing heart rate variability.
Full Text
##article.viewOnOriginalSite##About the authors
I. V Kochetkova
N.N.Burdenko Voronezh State Medical University of the Ministry of Health of the Russian Federation
Email: iri4217@yandex.ru
канд. мед. наук, ассистент каф. госпитальной терапии и эндокринологии ГБОУ ВПО ВГМУ им. Н.Н.Бурденко 394036, Russian Federation, Voronezh, ul. Studen- cheskaia, d. 10
T. M Chernykh
N.N.Burdenko Voronezh State Medical University of the Ministry of Health of the Russian Federationд-р мед. наук, зав. каф. госпитальной терапии и эндокринологии ГБОУ ВПО ВГМУ им. Н.Н.Бурденко 394036, Russian Federation, Voronezh, ul. Studen- cheskaia, d. 10
References
- Di Francesco D, Camm A. Heart rate Lowering by Specific and Selective If Current Inhibition with Ivabradin. Drugs 2004; 64: 1757-65.
- Borer J.S, Fox K, Jaillon P et al. Antianginal and antiischemic effects of ivabradine, an If ingibitor, in stable angina: randomized, double - blind, multicentered, placebo - controlled trial. Circulation 2003; 107: 817-23.
- On behalf of INITIATIVE study investigators group. Antianginal and anti - ischemic effects of the If current inhibitor ivabradine compared to atenolol as monotherapies in patients with chronic stable angina. Eur Heart J 2003; 24: Abstract 186.
- Fox K, Ford I, Steg P.G et al. Ivabradine for patients with stable coronary artery disease and left - ventricular systolic dysfunction (BEAUTIFUL): a randomised, double - blind, placebo - controlled trial. Lancet 2008. doi: 10.1016/S0140 6736(08)61170 8.
- Коломоец Н.М., Бакшеев В.И., Зарубина Е.Г. Клиническая эффективность ивабрадина у пациентов с ишемической болезнью сердца в сочетании с хронической обструктивной болезнью легких. Кардиология. 2008; 3: 13-9.
- Васюк Ю.А., Школьник Е.Л., Лебедев Е.В. Возможности ингибитора If - каналов ивабрадина в комплексном лечении больных стабильной стенокардией, перенесших инфаркт миокарда. Кардиология. 2010; 5: 13-7.
- Маколкин В.И., Петрий В.В., Андержанова А.А., Дранко О.Н. Опыт применения ивабрадина в клинической практике. Кардиология. 2008; 6: 24-8.
- Tardif J.C, Ford I, Tendera M et al. Long - term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109: 1674-9.
